Despite promising anti-tumor effects in preclinical models [1, 2], soluble TRAIL (sTRAIL) as well as agonistic antibodies against the two death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) did not show therapeutic activity in clinical trials [3]. Here, TNFRSF10A is linked to neoplasm.